Class summary at a glance.

Every drug in the Short-Acting Beta-2 Agonist (Bronchodilator) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $1.05Bcombined across class
Total Rx claims: 32.4M13.3M unique beneficiaries
Generic mfrs (active): 25across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Albuterol

Brand: Albuterol · 32.4M Part D claims (CY24) · 13.3M beneficiaries · First FDA approval: 1989-12-05

25 generic mfrs 1307 plans require PA Active FDA shortage

Low NADAC$0.032

→

Avg plan cost$1.52

Part D spend $1.05B 47× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.